

29 OCTOBER 2021

JOBKEEPER PAYMENTS FY2021 & FY2020

ASX ANNOUNCEMENT

Little Green Pharma Ltd (ASX: LGP, “LGP” or the “Company”) makes this announcement in accordance with subsection 323DB(1) of the *Corporations Act 2001*, which requires listed entities to notify the market if it or any subsidiaries (“Group”) have received a Jobkeeper payment (as defined by the *Coronavirus Economic Response Package (Payments and Benefits) Rules 2020*) during a financial year.

The notice confirms the Jobkeeper payments the Group received during financial years ending 30 June 2020 (“FY2020”) and 30 June 2021 (“FY2021”):

	FY2021	FY2020
The number of individuals that received a Jobkeeper payment for a Jobkeeper fortnight	Twenty-one (21)	Twenty (20)
The sum of all Jobkeeper payments received in each financial year	\$214,500.00	\$120,000.00
Whether or not the Group has made one or more voluntary payments to the Commonwealth by way of a repayment of Jobkeeper payments received in the financial year	The Group has not made any voluntary payments	The Group has not made any voluntary payments

ENDS



BY ORDER OF THE BOARD

A handwritten signature in black ink, appearing to read "Alistair Warren".

Alistair Warren
Company Secretary

For further information please contact:

Alistair Warren
Company Secretary
Little Green Pharma
E: a.warren@lgp.global
T: +61 8 6280 0050

Fleta Solomon
Managing Director
Little Green Pharma
E: f.solomon@lgp.global
T: +61 8 6280 0050



About Little Green Pharma

Little Green Pharma is a global, vertically integrated and geographically diverse medicinal cannabis and psychedelics business with operations from cultivation and production through to manufacturing and distribution.

The Company has two global production sites for the manufacture of its own-branded and white-label ranges of GMP-grade medicinal cannabis products, being a 21,500m² cultivation and 4,000m² GMP manufacturing facility capable of producing over 20 tonnes of medicinal cannabis biomass per annum located in Denmark (EU) and an indoor cultivation and manufacturing facility over located in Western Australia capable of producing ~3 tonnes of medicinal cannabis biomass per annum. The Company is also licensed to supply psilocybin and is presently expanding its WA production facilities to produce psilocybin medicines.

Little Green Pharma cannabis products comply with all required Danish Medicines Agency and Therapeutic Goods Administration regulations and testing requirements. With a growing range of products containing differing ratios of active ingredients, Little Green Pharma supplies medical-grade cannabis products to Australian, European and overseas markets.

The Company has a strong focus on patient access in the emerging global medicinal cannabis market and is actively engaged in promoting education and outreach programs, as well as participating in clinical investigations and research projects to develop innovative new delivery systems.

For more information about Little Green Pharma go to: www.littlegreenpharma.com

Help us be Green

LGP investors are encouraged to go paperless and receive Company communications, notices and reports by email. This will ensure efficient communication during COVID-19 while also helping to reduce our costs and environmental footprint.

To easily update your communication preferences, visit: www.computershare.com.au/easyupdate/lgp